Semaglutide reduced cardiovascular events by 20% in certain adults
Findings from a multi-center, international clinical trial reported by a Cleveland Clinic physician show that semaglutide reduced cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease who do not have diabetes.
Semaglutide is primarily prescribed for adults with type 2 diabetes but is also approved for chronic weight management in adults with obesity or overweight and have at least one other health issue. In the trial, patients treated with semaglutide lost an average of 9.4% of their body weight and experienced improvements in other risk factors for cardiovascular disease.
Results from the “SELECT — Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity Who Do Not Have Diabetes” trial were presented today during a late-breaking science session at the American Heart Association’s Scientific Sessions 2023 and simultaneously published in the New England Journal of Medicine.
In the trial, for patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly injections of semaglutide at a dose of 2.4 mg was superior to placebo in reducing the risk of death from cardiovascular causes, nonfatal heart attack, or nonfatal stroke over an average follow-up of 40 months.
“It is known that overweight and obesity increase a person’s risk of cardiovascular events. Yet while reducing cardiovascular disease by treating high cholesterol, high blood pressure, and diabetes is standard practice, the concept of treating obesity to reduce cardiovascular complications has been hampered by the lack of evidence that lifestyle or pharmacologic interventions for overweight or obesity improve cardiovascular outcomes,” said Michael Lincoff, M.D., SELECT’s lead author and vice chair for research in Cleveland Clinic’s Department of Cardiovascular Medicine. “This marks the first pharmacologic intervention for overweight or obesity that’s been shown in a rigorous fashion to reduce the risk of cardiovascular events.”
More than half the world population is projected to have overweight or obesity by the year 2035. High body-mass index (BMI) is estimated to have accounted for 4 million deaths globally in 2015, more than two thirds of which were caused by cardiovascular diseases.
Semaglutide, a GLP-1 receptor agonist medication initially approved and most frequently prescribed for adults with type 2 diabetes, was also FDA-approved in 2021 for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. While the weight loss effects of semaglutide appear to occur primarily through appetite suppression, this drug has other actions which may reduce cardiovascular risk, including improvements in glucose levels, decreases in blood pressure and cholesterol levels and reductions in inflammation, and beneficial effects on heart muscle and blood vessels.

